Search 

Biochemst from the Universidad de Chile, and dr rer Nat at TU Braunschweig, Germany. Currently Deputy Director of the Biotechnology Center and professor at the Forest Science Faculty at the Universidad de Concepcion Chile. Main area of R&D&i genomics and biosafety of GMOs. PI of several R&D proposals with companies, in the area of forest genomics. 

Have been co-founder of two spin-offs Genomica Forestal and DiagnoChrome. The latter focused on the development of detection kits for plant pathogens. 

Civil engineer in biotechnology, bilingual and graduated from postgraduate programs in the areas of chemistry and biotechnology. Positive, proactive and efficient, with great interest in learning about new areas. With a productive career, focused primarily on biotechnology and the chemical industry; management and innovation, related with the postgraduate studies and with independent projects (production of hyaluronic acid from bacteria; optimization microorganisms cultures; development of a ELISA Kit for salmon; collagen extraction from cuttlefish; Lobesia botrana trap and repellent, CORFO Projects, HibridaLab, Hospital SCM, etc.). A particular training in innovation and entrepreneurship in the last years has allowed to develop the ability to work guiding different interdisciplinary groups, mainly associated with emerging projects and structuring business models. With special interest in the formulation and development of innovation projects within and outside companies, particularly related with the biotechnology industry, health and process engineering.

Prof. Edwin CHAN from the School Life Sciences from the Chinese University of Hong Kong is working on rare neurodegenerative diseases including the Huntington’s Disease (HD). He recently developed a new inhibitor for the treatment of HD. This patented technology is known as P3. P3 is a 13-amino acid peptidylic inhibitor that can potently suppress expanded Polyglutamine (PolyQ) / CAG RNA-induced nucleolar stress, and rescue neurodegeneration in animal disease model and cell death in patient fibroblasts.

The core benefits of this technology are:

(1)   the inhibitor is capable of directly interacting with and neutralizing the toxic expanded PolyQ / CAG RNA,

(2)   the mechanism of this inhibitor is well-defined that it reduces cellular p53 level and suppresses caspase activities, and

(3)   with proven potential to treat other polyglutamine diseases, such as spinocerebellar ataxias (SCA).

Related patent and references:

(1)   Zhang et al, Dis. Model. Mech, 2016 (http://www.ncbi.nlm.nih.gov/pubmed/26839389)

(2)   Tsoi et al, PNAS, 2012 (http://www.ncbi.nlm.nih.gov/pubmed/22847428)

(3)   US9,297,798 (http://www.google.com/patents/US9297798)

(4)   US Provisional patent (Priority date: 23 Dec 2015)

(5)   US non-Provisional patent (Priority date: 17 Feb 2016)

More details:

(1)   Introduction Slides: http://goo.gl/RSZf7g

(2)   Introduction Brochure: http://goo.gl/IdbVRG

(3)  Introduction Videos: https://goo.gl/nfZAbK